News
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...
A study from Mass General Brigham and Harvard Medical School raises questions about a new class of weight loss drugs — and ...
Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...
Starting on a weight loss medication has helped Joie Armstrong prioritize caring for herself, including finding more ...
Tribune News Service on MSN7h
On Nutrition: Don’t miss the fine print on weight-loss drugsI hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...
Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...
Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.
As medications like Ozempic transform the health of millions of Americans, some families are discovering a surprising side ...
It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...
Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.
Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results